recent transactionshistorical transactions
Xanodyne Pharmaceuticals, Inc.
Financing of specialty pharmaceutical company focused on women's healthcare and pain management

October 2009
Security:
Series B Preferred
Location: Newport, KY

Case Study    Press Release


President CEO: Michael Valentino
CFO: Rita O’Connor
CMO: Gary Shangold
CCO: Natasha Giordano

New Investors: Longitude Capital, Silver Point Capital, Skandia Asset Management
Existing Investors: AIG Global, Aisling Capital, Apax Partners, Blue Chip Venture, Essex Woodlands Health Ventures, HealthCare Ventures, MPM Capital, Union Springs
Board of Directors: Rolf Classon, Vaughn Kailian, Dennis Purcell, Steven St. Peter, James Shannon, Craig Tooman, Michael Valentino

- Commercial stage company with:

  • Significant pain franchise
  • Zipsor recently launched
  • Lysteda NDA filed